ArticleThe Pediatric infectious disease journal2026
Epigenetic Age Acceleration, Neurocognition and Oral Health in Nigerian Adolescents With and Without HIV.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPeople living with HIV on antiretroviral therapy (ART) experience neurocognitive impairments, oral disease and epigenetic age acceleration (EAA) at higher rates than the general population. The objective of this study was to examine the associations between EAA and measures of neurocognition and oral health among adolescents living with HIV (ALHIV) and matched controls.
methodsThe Uncovering the Biological Link Between Oral and Mental Health in Adolescents Living With HIV study enrolled 116 adolescents (10-13 years old) at the University of Benin Teaching Hospital in Nigeria. Fifty-eight ALHIV and 58 age- and sex-matched HIV-unexposed-uninfected participants were included in this cross sectional analysis. Participants completed two neurocognitive tests, NeuroScreen and NIH Toolbox Cognition Battery, and clinical oral exams. Peripheral blood DNA underwent methylation profiling, and epigenetic age and EAA were calculated with six validated algorithms (Horvath1, Horvath2, Hannum, PhenoAge, GrimAge and PedBE).
resultsIn adjusted models among all participants and ALHIV, EAA was associated with poorer verbal learning/encoding scores. Among ALHIV, EAA (GrimAge) was inversely associated with processing speed [number speed; ß, -2.58 (95% confidence interval: -4.22 to -0.94)]. Inverse and positive associations between EAA and neurocognition assessed by the NIH Toolbox were detected. Higher EAA was not significantly associated with poorer oral health in this population.
conclusionsEAA may be linked to diminished processing speed and verbal learning in ALHIV on antiretroviral therapy. Oral disease was not strongly linked to EAA in this study. These findings indicate the need for longitudinal studies of EAA and neurocognitive and oral health outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.